Meditor Group LTD Exelixis, Inc. Transaction History

Meditor Group LTD

$48.1 Million
Q3 2024

A detailed history of Meditor Group LTD transactions in Exelixis, Inc. stock. As of the latest transaction made, Meditor Group LTD holds 1,362,450 shares of EXEL stock, worth $39.1 Million. This represents 73.43% of its overall portfolio holdings.

Number of Shares

1,362,450

Previous 1,753,000 22.28%

Holding current value

$39.1 Million

Previous $39.4 Million 10.24%

% of portfolio

73.43%

Previous 72.88%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 07, 2024	SELL	$21.96 - $27.6 $8.58 Million - $10.8 Million	-390,550 Reduced 22.28%	1,362,450 $35.4 Million
Q2 2024 Jul 22, 2024	SELL	$20.34 - $23.73 $9.07 Million - $10.6 Million	-445,800 Reduced 20.27%	1,753,000 $39.4 Million
Q1 2024 Apr 11, 2024	SELL	$20.17 - $23.93 $8.86 Million - $10.5 Million	-439,500 Reduced 16.66%	2,198,800 $52.2 Million
Q4 2023 Jan 04, 2024	SELL	$19.25 - $24.13 $9.62 Million - $12.1 Million	-499,900 Reduced 15.93%	2,638,300 $63.3 Million
Q3 2023 Oct 31, 2023	SELL	$19.04 - $22.74 $38 Million - $45.4 Million	-1,997,558 Reduced 38.9%	3,138,200 $68.6 Million
Q2 2023 Jul 25, 2023	SELL	$18.17 - $20.48 $5.04 Million - $5.68 Million	-277,142 Reduced 5.12%	5,135,758 $98.1 Million
Q1 2023 Apr 10, 2023	SELL	$16.3 - $19.41 $22.9 Million - $27.2 Million	-1,403,400 Reduced 20.59%	5,412,900 $105 Million
Q3 2022 Nov 07, 2022	SELL	$15.68 - $22.27 $14.2 Million - $20.1 Million	-904,000 Reduced 11.71%	6,816,300 $107 Million
Q2 2022 Jul 18, 2022	SELL	$17.44 - $23.16 $22 Million - $29.3 Million	-1,264,000 Reduced 14.07%	7,720,300 $161 Million
Q1 2022 Apr 12, 2022	SELL	$17.03 - $22.67 $17.8 Million - $23.7 Million	-1,046,400 Reduced 10.43%	8,984,300 $204 Million
Q4 2021 Jan 05, 2022	SELL	$15.84 - $21.88 $10.9 Million - $15.1 Million	-688,700 Reduced 6.42%	10,030,700 $183 Million
Q2 2021 Jul 12, 2021	SELL	$17.95 - $25.56 $9.99 Million - $14.2 Million	-556,471 Reduced 4.94%	10,719,400 $195 Million
Q1 2021 Apr 09, 2021	SELL	$20.53 - $25.22 $27.4 Million - $33.7 Million	-1,334,669 Reduced 10.58%	11,275,871 $255 Million
Q4 2020 Jan 06, 2021	SELL	$18.39 - $24.8 $4.25 Million - $5.74 Million	-231,258 Reduced 1.8%	12,610,540 $253 Million
Q2 2020 Jul 14, 2020	SELL	$16.46 - $27.42 $25.9 Million - $43.1 Million	-1,572,075 Reduced 10.91%	12,841,798 $305 Million
Q1 2020 Apr 30, 2020	SELL	$14.46 - $21.8 $8.49 Million - $12.8 Million	-587,200 Reduced 3.91%	14,413,873 $200 Million
Q2 2019 Jul 24, 2019	SELL	$18.93 - $24.75 $1.77 Million - $2.31 Million	-93,422 Reduced 0.62%	15,001,073 $321 Million
Q1 2019 Apr 03, 2019	SELL	$19.6 - $24.76 $17.1 Million - $21.6 Million	-871,543 Reduced 5.46%	15,094,495 $359 Million
Q1 2018 Apr 20, 2018	SELL	$22.15 - $31.89 $11.5 Million - $16.5 Million	-518,600 Reduced 3.15%	15,966,038 $354 Million
Q4 2017 Jan 03, 2018	SELL	$24.23 - $30.93 $22.6 Million - $28.8 Million	-932,100 Reduced 5.35%	16,484,638 $501 Million
Q3 2017 Oct 17, 2017	BUY	$23.35 - $29.24 $407 Million - $509 Million	17,416,738	17,416,738 $422 Million

Others Institutions Holding EXEL

# of Institutions

466

Shares Held

239M

Call Options Held

2.04M

Put Options Held

1.29M

View Full List

About EXELIXIS, INC.

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $9.25B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

More about EXEL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Meditor Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Meditor Group LTD with notifications on news.

Account

Meditor Group LTD Exelixis, Inc. Transaction History